Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

RZLT Relative to the S&P 500

RZLT Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Rezolute, Inc. (NASD:RZLT) seasonal charts above shows that a Buy Date of May 24 and a Sell Date of August 31 has resulted in a geometric average return of 16.22% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 44.7% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm’s antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

To download RZLT seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: RZLT